AI Terminal
Aladdin Healthcare Technologies SE
Regulatory Filings • Feb 24, 2021
23_rns_2021-02-24_dea38986-f8e4-4813-a669-ca43daee71ce.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 24 February 2021 07:59
Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China
DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Patent/Miscellaneous
24.02.2021 / 07:59
The issuer is solely responsible for the content of this announcement.
Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China
– Aladdin has developed patented AI-platform together with its partner IIAT in China
– The innovative AI-driven platform marks a turning point in the early diagnostics of heart diseases
– Next step is gaining patent approval also in the USA and Europe
BERLIN/LONDON February 24, 2021 – Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has developed together with its partner IIAT (Imperial Institute of Advanced Technology) an innovative AI-powered data analysis platform for cardiovascular diseases. The platform has just successfully gained three patents in China.
Aladdin achieves a milestone in the early diagnostics of cardiovascular diseases. By combining multimodal data specifically integrated AI-driven blood analysis, the Company brings a novel approach of early diagnostics to market. Moreover, most other currently available AI approaches reflect the reliance of the industry on utilising cardiac images as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple complexities that involve the disease and its underlying pathways.
The AI-data platform has gained three patents in China that include:
a. Automated Multimodal Cardiac Image Analysis, Visualisation and 3D Printing
b. Multiscale Auto-focused Super-resolution
c. High-resolution Myocardial Motion Analysis System
The IIAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies as well as projects in the field of healthcare from Europe to China and promoting them in China.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: “The achievement of three patents in China is a further acknowledgment of our ability in improving the world of healthcare diagnostics with our expertise and together with our important network of international partners.” Under the agreement with IIAT, Aladdin has all international rights to license the AI-technology in Europe, UK and the USA, but not in China. The Company is planning to seek patent approval in the USA and Europe as next step.
As part of the new international growth strategy, Aladdin will list its shares on the OTC market in the USA.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI
For further information:
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: [email protected]
Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: [email protected]
24.02.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Aladdin Healthcare Technologies SE |
| Unter den Linden 10 | |
| 10117 Berlin | |
| Germany | |
| Phone: | 030 700140449 |
| E-mail: | [email protected] |
| Internet: | www.aladdinid.com |
| ISIN: | DE000A12ULL2 |
| WKN: | A12ULL |
| Listed: | Regulated Market in Dusseldorf |
| EQS News ID: | 1170650 |
| End of News | DGAP News Service |